P-410 Factors affecting progression-free survival (PFS) for patients with metastatic colorectal cancer (mCRC) receiving regorafenib or for patients after re-challenge previously effective chemotherapy (CT) regimens in third or following lines

Regorafenib is considered the standard third-line therapy of mCRC, which has demonstrated a survival benefit over placebo in randomized trials. Another, less proven approach to re-challenge previously effective treatment regimens. We compared factors associated with longer PFS use regorafenib and chemotherapy mCRC. analyzed prospective database pts mCRC from two clinics Russian Federation. conducted univariate then multivariate analysis affecting group patients treated third or following lines receiving statistical SPSS software package (v. 20, IBM). In database, we identified 215 morphologically confirmed metastatic colon cancer who received more antitumor drug 2010 2021. Of them, selected 132 history therapy, 83 rechallenge CT as line therapy. Overall (OS) groups did not differ (hazard ratio [HR] 1.01 95% CI 0.7-1.45; p=0.9) 6-month OS was 74 70%, respectively. Progression-free significantly higher (HR 1.94 95%CI 1.3-2.7; p < 0.001); multifactorial surgical resection primary tumor factor, that improved 0,5; 0,3-0,9; p=0,05). Deteriorating were liver metastasis 1,7; 1,1-2,6; p=0,01) ECOG performance status 1-2 1,4; 1,08-2,06; p=0,01). As result improving were: stage Т1-2 0,4; 0,2-0,7; p=0,002), surgery for 0,2-0,9; p=0,02), lung metastases 0,04; p=0,04). worsened CI; 1,0-2,9; The best rates are prognostic rather than predictive, make it possible identify an indolent course disease good appointment lines.